June 5 (Reuters) - The companies manufacturing COVID-19

vaccines said data from animals studies showed their 2024-25

shots targeting the JN.1 variant that was dominant earlier this

year could neutralize newer subvariants such as KP.2 much better

than the older shots.

Pfizer ( PFE ) and its partner BioNTech will be

ready to supply the updated vaccines immediately upon approval,

while Moderna ( MRNA ) and Novavax ( NVAX ) forecast a timeline

for August.

This was disclosed in a presentation by the companies ahead

of a meeting of the U.S. Food and Drug Administration's advisers

on Wednesday.

(Reporting by Christy Santhosh and Leroy Leo in Bengaluru;

Editing by Arun Koyyur)